RUA Life Sciences plc provided earnings guidance for the 12 months to 31 March 2022. For the period, the company expected to have generated consolidated unaudited revenues of £1,625,000 (2021: £1,528,000), an increase of 6% over the same period in the previous year. Overall, loss before tax for the period is expected to have increased to £2,360,000 (2021: £1,594,000) which resulted from a combination of increased R&D activities and further investment in the infrastructure to support future growth.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11 GBX | 0.00% |
|
+1.15% | +11.68% |
06-19 | EARNINGS AND TRADING: Zambeef names new Chair | AN |
04-05 | RUA Life Sciences expects flat annual revenue on strong second half | AN |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+11.68% | 8.63M | |
+8.00% | 185B | |
+31.86% | 158B | |
+33.21% | 113B | |
+2.28% | 64.32B | |
+21.14% | 55.66B | |
+0.11% | 48.41B | |
-6.76% | 37.82B | |
+0.78% | 35.57B | |
+11.28% | 28.12B |
- Stock Market
- Equities
- AOR Stock
- News RUA Life Sciences plc
- Rua Life Sciences plc Provides Earnings Guidance for the 12 Months to 31 March 2022